Oncolytics’ Reolysin Receives FDA Fast Track Designation for Metastatic Breast Cancer

Oncolytics’ Reolysin Receives FDA Fast Track Designation for Metastatic Breast Cancer
The U.S. Food and Drug Administration has granted fast track status to Reolysin for treating metastatic breast cancer, according to its developer, Oncolytics Biotech. Fast track accelerates the review of therapies for serious conditions with unmet medical needs. It will enhance the dialogue between the FDA and Oncolytics on the company’s drug development plans, information required

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *